A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients
Abstract Background: Cardiotoxicity is an important side effect of trastuzumab therapy and cardiac surveillance is recommended. Objectives: The aim of our study was to prospectively assess baseline patients' characteristics, level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and ec...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sociedade Brasileira de Cardiologia (SBC)
2016-01-01
|
| Series: | Arquivos Brasileiros de Cardiologia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016005016102&lng=en&tlng=en |
| _version_ | 1818218376626962432 |
|---|---|
| author | Erika Matos Borut Jug Rok Blagus Branko Zakotnik |
| author_facet | Erika Matos Borut Jug Rok Blagus Branko Zakotnik |
| author_sort | Erika Matos |
| collection | DOAJ |
| description | Abstract Background: Cardiotoxicity is an important side effect of trastuzumab therapy and cardiac surveillance is recommended. Objectives: The aim of our study was to prospectively assess baseline patients' characteristics, level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and echocardiographic parameters as possible predictors of trastuzumab-related cardiac dysfunction. Methods: In a prospective cohort study, clinical, echocardiographic and neurohumoral assessment was performed at baseline, after 4, 8 and 12 months in breast cancer patients undergoing post-anthracycline (3-4 cycles) adjuvant therapy with trastuzumab. Trastuzumab-related cardiac dysfunction was defined as a decline of ≥ 10% in left ventricular ejection fraction (LVEF). Results: 92 patients (mean age, 53.6 ± 9.0 years) were included. Patients who developed trastuzumab-related LVEF decline ≥ 10% (20.6%) during treatment had significantly higher baseline LVEF (70.7 ± 4.4%) than those without (64.8 ± 5.5%) (p = 0.0035). All other measured baseline parameters (age, body mass index, arterial hypertension, level of NT-proBNP and other echocardiographic parameters) were not identified as significant. Conclusions: Our findings suggest that baseline patient' characteristics, level of NT-proBNP and echocardiographic parameters, as long as they are within normal range, are not a reliable tool to predict early trastuzumab-related cardiac dysfunction in patients undergoing post-low dose anthracycline adjuvant trastuzumab therapy. A LVEF decline in patients with high-normal baseline level although statistically significant is not clinically relevant. |
| first_indexed | 2024-12-12T07:22:47Z |
| format | Article |
| id | doaj.art-a367d4cec17e485995d3740fbadb818b |
| institution | Directory Open Access Journal |
| issn | 1678-4170 |
| language | English |
| last_indexed | 2024-12-12T07:22:47Z |
| publishDate | 2016-01-01 |
| publisher | Sociedade Brasileira de Cardiologia (SBC) |
| record_format | Article |
| series | Arquivos Brasileiros de Cardiologia |
| spelling | doaj.art-a367d4cec17e485995d3740fbadb818b2022-12-22T00:33:16ZengSociedade Brasileira de Cardiologia (SBC)Arquivos Brasileiros de Cardiologia1678-41702016-01-01010.5935/abc.20160084S0066-782X2016005016102A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer PatientsErika MatosBorut JugRok BlagusBranko ZakotnikAbstract Background: Cardiotoxicity is an important side effect of trastuzumab therapy and cardiac surveillance is recommended. Objectives: The aim of our study was to prospectively assess baseline patients' characteristics, level of N-terminal pro-brain natriuretic peptide (NT-proBNP) and echocardiographic parameters as possible predictors of trastuzumab-related cardiac dysfunction. Methods: In a prospective cohort study, clinical, echocardiographic and neurohumoral assessment was performed at baseline, after 4, 8 and 12 months in breast cancer patients undergoing post-anthracycline (3-4 cycles) adjuvant therapy with trastuzumab. Trastuzumab-related cardiac dysfunction was defined as a decline of ≥ 10% in left ventricular ejection fraction (LVEF). Results: 92 patients (mean age, 53.6 ± 9.0 years) were included. Patients who developed trastuzumab-related LVEF decline ≥ 10% (20.6%) during treatment had significantly higher baseline LVEF (70.7 ± 4.4%) than those without (64.8 ± 5.5%) (p = 0.0035). All other measured baseline parameters (age, body mass index, arterial hypertension, level of NT-proBNP and other echocardiographic parameters) were not identified as significant. Conclusions: Our findings suggest that baseline patient' characteristics, level of NT-proBNP and echocardiographic parameters, as long as they are within normal range, are not a reliable tool to predict early trastuzumab-related cardiac dysfunction in patients undergoing post-low dose anthracycline adjuvant trastuzumab therapy. A LVEF decline in patients with high-normal baseline level although statistically significant is not clinically relevant.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016005016102&lng=en&tlng=enTrastuzumab / efeitos adversosTrastuzumab / uso terapêuticoNeoplasias da Mama / terapiaCardiotoxicidadeEstudos de Coortes |
| spellingShingle | Erika Matos Borut Jug Rok Blagus Branko Zakotnik A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients Arquivos Brasileiros de Cardiologia Trastuzumab / efeitos adversos Trastuzumab / uso terapêutico Neoplasias da Mama / terapia Cardiotoxicidade Estudos de Coortes |
| title | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| title_full | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| title_fullStr | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| title_full_unstemmed | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| title_short | A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients |
| title_sort | prospective cohort study on cardiotoxicity of adjuvant trastuzumab therapy in breast cancer patients |
| topic | Trastuzumab / efeitos adversos Trastuzumab / uso terapêutico Neoplasias da Mama / terapia Cardiotoxicidade Estudos de Coortes |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0066-782X2016005016102&lng=en&tlng=en |
| work_keys_str_mv | AT erikamatos aprospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT borutjug aprospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT rokblagus aprospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT brankozakotnik aprospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT erikamatos prospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT borutjug prospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT rokblagus prospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients AT brankozakotnik prospectivecohortstudyoncardiotoxicityofadjuvanttrastuzumabtherapyinbreastcancerpatients |